- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:diseases:als [01.04.2019] – [Cell Wall-Deficient (CWD) Bacterial Pathogens: Could Amyotrophic Lateral Sclerosis (ALS) Be Due to One?] sallieq | home:diseases:als [02.11.2019] – [Evidence of infectious cause] sallieq | ||
|---|---|---|---|
| Line 42: | Line 42: | ||
| Neuropharmacology Vol.13 No 8 12 June 2002 Ludo Van Den Bosch, Petra Tilkin, Griet Lemmns and Wim Robberecht Laboratory of Neurology, Campus Gasthuisberg, | Neuropharmacology Vol.13 No 8 12 June 2002 Ludo Van Den Bosch, Petra Tilkin, Griet Lemmns and Wim Robberecht Laboratory of Neurology, Campus Gasthuisberg, | ||
| - | < | + | < |
| - | + | ||
| - | http:// | + | |
| Although we found that the potential of these cells is more limited than previously thought, it might be possible to coax them to adopt different fates," | Although we found that the potential of these cells is more limited than previously thought, it might be possible to coax them to adopt different fates," | ||
| Line 63: | Line 61: | ||
| ===== Patient experiences ===== | ===== Patient experiences ===== | ||
| - | **Active patients** | + | ** Active patients ** |
| * Chris Mavo: | * Chris Mavo: | ||
| - | //Last contact: July, 2018// see [[http:// | + | //Last contact: July, 2018// see [[http:// |
| - | **Patient | + | ** Patient |
| * //there are no patient interviews with ALS// | * //there are no patient interviews with ALS// | ||
| + | |||
| + | |||
| + | |||
| + | - Scottk, our earliesst member with ALS, dropped antibiotics and trialed chlorine dioxide (MMS) in conjunction with Benicar and reports a possible improvement in his toes. He then returned to using just the MP again. He stayed on the MP for 3 ½ years in total | ||
| + | |||
| + | < | ||
| + | I continued benicar throughout. after a day of MMS I could straighten my toes which I could not before and I still can now that I have stopped MMS and resumed the full mp. My walking improved also but I am unsure if that was from stopping the abx/ip. so far the improvement in my walking has remained. | ||
| + | |||
| + | An interesting thing is that my photosensitivity has returned so it is not the benicar alone that causes it in me, it is benicar and abx.</ | ||
| + | |||
| + | |||
home/diseases/als.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.